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Abstract: Hypertension is one of the most prevalent and powerful contributors of cardiovascular
diseases. Malignant hypertension is a relatively rare but extremely severe form of hypertension
accompanied with heart, brain, and renal impairment. Resveratrol, a recently described grape-
derived, polyphenolic antioxidant molecule, has been proposed as an effective agent in the prevention
of cardiovascular diseases. This study was designed to examine chronic resveratrol administration
on blood pressure, oxidative stress, and inflammation, with special emphasis on cardiac structure
and function in two models of experimental hypertension. The experiments were performed in
spontaneously (SHRs) and malignantly hypertensive rats (MHRs). The chronic administration of
resveratrol significantly decreased blood pressure in both spontaneously and malignant hypertensive
animals. The resveratrol treatment ameliorated morphological changes in the heart tissue. The
immunohistochemistry of the heart tissue after resveratrol treatment showed that both TGF-β and
Bax were not present in the myocytes of SHRs and were present mainly in the myocytes of MHRs.
Resveratrol suppressed lipid peroxidation and significantly improved oxidative status and release
of NO. These results suggest that resveratrol prevents hypertrophic and apoptotic consequences
induced by high blood pressure with more pronounced effects in malignant hypertension.
Keywords: resveratrol; spontaneously and malignant hypertension; heart
1. Introduction
Cardiovascular diseases represent the first cause of mortality in the Western world and,
due to this, particular attention is paid to them in both the scientific world and in the public
opinion. Epidemiological studies have demonstrated that hypertension, as a significant
cardiovascular risk factor, represents the main cause of death and, in the general population,
it affects from 30% to 45% of people, with a tendency to increase incidence from the age of
50. Malignant hypertension is a particularly severe form of arterial hypertension defined by
extremely high systolic and diastolic arterial pressure (SAP > 200 ± DAP > 130 mmHg) [1].
In the general population, the prevalence of malignant hypertension is relatively low, but it
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had an extremely severe prognosis considering ≈80% mortality in 2 years [2]. Despite the
serious character of malignant hypertension, it is not studied enough.
The spontaneously hypertensive rats (SHRs) are widely used as a rat model of primary
or essential hypertension. They have a similar vascular anatomy and structure as humans
characterized by altered vascular tone, increased vascular contractility, and long-term,
stable cardiovascular structural remodeling [3,4]. Malignant hypertension can develop
from essential hypertension through serious long-term inhibition of endothelium-derived,
vasodilatory, nitric oxide (NO). In particular, persistent NG-L-Arginine Methyl Ester (L-
NAME) (Figure 1B) inhibition of NO biosynthesis in SHRs leads to a significant increase
in blood pressure followed by profound vasoconstriction, oxidative stress, and structural
alterations of the conduit and large arteries, as well as cardiac hypertrophy [4–6].
Figure 1. Graphical experimental layout (A), chemical formulas (B), systolic arterial pressure-SAP (C), heart rate-HR (D),
cardiac output-CO (E) and total vascular resistance-TVR (F) in experimental groups. SHR-spontaneously hypertensive rat;
SHR + R-spontaneously hypertensive rat treated with resveratrol; MHR-malignant hypertensive rat; MHR + R-malignant
hypertensive rat treated with resveratrol. Values are means ± SD. ***, **, * indicate p < 0.001, 0.01, 0.05.
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Untreated high blood pressure can contribute to vascular remodeling via structural
and functional changes within the arterial wall [7,8] and induced endothelial dysfunction
has been attributed to reducing NO bioavailability [8]. Reduced NO availability and vaso-
constriction in the hypertensive condition induces oxidative misbalance. Oxidative stress
is defined as “an imbalance between oxidants and antioxidants in favor of the oxidants,
leading to a disruption of redox signaling and uncontrolled reactive oxygen species (ROS)
production” [8]. ROS induce protein oxidation and dysregulate cell signaling, leading
to inflammation, proliferation, fibrosis, and apoptosis, which are important processes
contributing to impaired vascular function and cardiovascular remodeling in hyperten-
sion [9]. Additionally, hypertension has been shown to increase neutrophil activation [10].
Neutrophils and monocytes normally produce and release myeloperoxidase (MPO) [11].
Elevated level of MPO reflects the degree of neutrophil activation and it has been associated
with vascular dysfunction [12]. Additionally, MPO is involved in the formation of ROS and
the oxidation of biological material [13]. The above findings suggest that elevated levels of
MPO could be observed in hypertension.
Transforming growth factor-beta (TGF-β) is a locally generated cytokine that plays
a mediator role in promoting alterations in vessel structure [14]. It is found in all cell
types of the cardiovascular system, including cardiac myocytes, vascular smooth muscle,
endothelial cells, fibroblasts, and blood cells [15]. The endothelial cell dysfunction in
hypertension relates to the abundance of TGF-β in the arterial wall, which promotes intimal
proliferation as well as the development of vascular lesions accompanied by apoptosis in
the vascular smooth muscle cells [5].
The Bcl-2 proteins can localize to different organelles including the endoplasmic
reticulum, the Golgi apparatus, the nuclear outer membrane, or the nucleus itself [16]. It
plays a role in the inhibition of apoptosis [17]. On the other side, Bax, a member of the Bcl-2
family, promotes apoptotic death. The ratio of Bcl-2 to Bax determines survival or death
after an apoptotic stimulus [16]. Thus, we speculated that Bcl-2 or Bax overexpression
can induce elevated blood pressure and may also cause myocyte death in hearts of rat in
different models of hypertension.
More scientists highlighted that some components of the diet, including polyphenols,
show a protective effect on the onset of cardiovascular disease (CVD) [18]. Several studies
have shown that low to moderate wine intake had been associated with lower mortality
from cardiovascular and cerebrovascular diseases [19,20]. After these observations, a
great deal of attention has been paid to red wine [21]. The cardioprotective effects of red
wine have been attributed to resveratrol [22]. Resveratrol (trans-3,4′,5-trihydroxystilbene,
C14H12O3) (Figure 1B) is a natural polyphenol found in many plant species including grapes
and a variety of berries. Several studies reported that resveratrol possessed antioxidant [23],
anti-inflammatory [24], and proapoptotic activity [25]. Dietary polyphenol, resveratrol, has
potential to improve endothelial dysfunction and decrease overall blood pressure [5,26]. In
the hypertensive condition, resveratrol decreases vascular oxidative stress by scavenging
H2O2 and preventing oxidative stress-induced endothelial cell death [27]. It is found that it
may activate endogenous defense systems and regulate cellular signaling processes [28].
Considering the aforementioned information, resveratrol seems to serve as an effective
dietary supplement for the protection and preservation of the aorta in different hyperten-
sive conditions. Therefore, this study has been designed to examine chronic resveratrol
administration on cardiac structure and function and correlate it with oxidative stress and
inflammation status of heart in the spontaneously (SHRs) and malignant hypertensive
(MHRs) rats.
2. Results
2.1. Body and LV and RV Weights
After the treatment, period body weight (b.w.) was comparable between all experimen-
tal groups (Table 1). However, both resveratrol treated SHRs and MHRs had significantly
lower body weights compared to vehicle treated control rats (p < 0.001; p < 0.05).
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Table 1. Left and right ventricular (LV and RV) weight and weight indexes (LVI and RVI).
SHR SHR + R MHR MHR + R
b.w. (g) 172.5 ± 3.11 147.5 ± 3.92 *** 152.08 ± 1.89 *** 162.92 ± 3.28 *, #, $
LV (g) 0.631 ± 0.012 0.526 ± 0.006 ***, ### 0.682 ± 0.02 ** 0.625 ± 0.008 ###, $$$
RV (g) 0.130 ± 0.004 0.108 ± 0.004 ***, ### 0.159 ± 0.005 *** 0.122 ± 0.004 ###, $
LVI (mg/g) 0.366 ± 0.011 0.337 ± 0.008 ### 0.438 ± 0.009 *** 0.413 ± 0.016 **, $$$
RVI (mg/g) 0.085 ± 0.006 0.069 ± 0.002 *, # 0.085 ± 0.003 0.081 ± 0.004
SHR—spontaneously hypertensive rat, SHR + R—spontaneously hypertensive rat treated with resveratrol; MH—malignant hypertensive
rat; MHR + R—malignant hypertensive rat treated with resveratrol. Values are means ± SEM. ***, **, * indicate p < 0.001, 0.01, 0.05 vs. SHR;
###, # indicate p < 0.001, 0.05 vs. MHR; $$$, $ indicate p < 0.001, 0.05 vs. SHR + R group.
Left (LV) and right ventricular (RV) weight and ventricular weight indexes (LVI; RVI)
were significantly higher in MHRs compared to SHRs (Table 1). After resveratrol treatment,
there were significant differences in LV and RV weights and ventricular weight indexes
compared to their respective controls (Table 1).
2.2. Hemodynamic Study
The data collected by hemodynamic measurement showed that systolic arterial pres-
sure (SAP) was 176.3 ± 4.69 mmHg in SHRs (Figure 1). Additionally, after 4 weeks of
blocked NO synthesis in MHR, SAP raised to 201.12 ± 1.74 mmHg. The application of
resveratrol significantly reduced this increase in both SHR and MHR groups (p < 0.001).
The cardiac output (CO) was significantly decreased, and total vascular resistance (TVR)
was significantly increased in the MHR compared with control groups (p < 0.001). Com-
pared to their respective controls, the CO increased significantly in the SHR + R and
MHR + R groups (47% to 29.4%, respectively) after resveratrol treatment. However, chronic
resveratrol treatments reduced TVR in both treated resveratrol groups. The heart rate (HR)
was not different between experimental groups. However, in malignant hypertensive
rats, resveratrol increased CO and reduced SAP as well as TVR almost to the value of the
control group.
2.3. Redox State
The thiobarbituric acid reactive substances (TBARSs) were significantly increased
in the MHR group, which had significantly higher advanced oxidation protein products
(AOPPs) compared to control group (Figure 2; p < 0.001; p < 0.01; respectively). Resveratrol
treatments induced a significant reduction in TBARSs as well as AOPP level in both treated
groups, SHR + R (p < 0.05, p < 0.01) and MHR + R, in comparison to their respective controls
(p < 0.001, p < 0.001).
In heart tissue of MHRs, the level of thiol groups increased significantly, by 30%,
compared with the SHR group (Figure 2). In the same MHR group, the superoxide
anion radical (O2−) and prooxidative balans (PAB) were significantly higher (p < 0.001,
p < 0.001) and the NO2 levels were significantly decreased (p < 0.01) compared with control.
Interestingly, the application of resveratrol improves redox status in both hypertensive
groups. Markedly enhanced the nitrite (NO2) levels (p < 0.001) and attenuated O2− as
well as thiol groups were seen in the SHR animals that received resveratrol (p < 0.001,
p < 0.05). A similar trend was maintained in the MHR + R group, the NO2 was significantly
higher (p < 0.001), but the level of superoxide anion and thiol groups were markedly lower
(p < 0.001, p < 0.001) compared to MHR. As expected, these parameters were significantly
better in SHR + R compared to MHR, and in MHR + R it was almost the value of the
control group.
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Figure 2. TBARSs-thiobarbituric acid reactive substances (A), AOPP-advanced oxidation protein products (B), PAB-
prooxidative balans (C), Thiol groups (D), O2−-superoxide anion radical (E), NO2−-nitrites (F) in experimental groups.
SHR-spontaneously hypertensive rat; SHR + R-spontaneously hypertensive treated with resveratrol; MHR-malignant
hypertensive rat; MHR + R-malignant hypertensive rat treated with resveratrol. Values are means ± SD. ***, **, * indicate
p < 0.001, 0.01, 0.05.
The blockade of NO syntheses decreased superoxide dismutase (SOD), catalase (CAT),
and glutathione peroxidase (GPx) activities in MHR compared to SHR (Figure 3). After
4 weeks, application of resveratrol significantly prevented the reduction in antioxidant
enzyme in SHR + R (p < 0.05; p < 0.01; p < 0.001) and MHR + R (p < 0.01; p < 0.001;
p < 0.01). As expected, resveratrol revealed significant improvement activity of antioxidant
enzyme as compared with MHR and its values showed no relevant differences compared
with control.
At 4 weeks, L-NAME treated SHRs had a significantly elevated level of MPO compared
with vehicle treated control rats (Figure 4, p < 0.01). As expected, resveratrol significantly
reduced MPO (p < 0.001) compared to SHR, as is the case in MHR + R compared to MHR
(Figure 4, p < 0.01). In the SHR + R group, the decrease in MPO was higher as compared
with MHR (p < 0.001), and the MHR + R group was similar to the SHR group.
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Figure 3. Antioxidative enzyme SOD-superoxide dismutase (A); CAT-catalase (B); GR-glutathione reductase (C) and
GPx-glutathione peroxidase (D) in experimental groups. SHR-spontaneously hypertensive rat, SHR + R-spontaneously
hypertensive treated with resveratrol; MHR-malignant hypertensive rat; MHR + R-malignant hypertensive rat treated with
resveratrol. Values are means ± SD. ***, **, * indicate p < 0.001, 0.01, 0.05.
Figure 4. MPO-myeloperoxidase enzyme activity (A) and CDS-Cardiomyocyte Damage Score (B) in experimental groups. SHR-
spontaneously hypertensive rat; SHR + R-spontaneously hypertensive treated with resveratrol; MHR-malignant hypertensive rat;
MHR + Rmalignant hypertensive rat treated with resveratrol. Values are means ± SD. *** indicate p < 0.001, ** p < 0.01.
2.4. Histopatological Parameters
The high blood pressure in SHRs leads to the partial vacuolar degeneration of the
endocardium and myocardium in hypertrophied myocytes, the altered muscle fibers
partially lost their transverse striations, and the cytoplasm is filled with clearly visible
vacuoles of various shapes, sizes, numbers, and arrangements, as well as the nuclei, which
are extremely basophilic, large without visible nucleoli. Histological changes were more
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intensive in MHR, with markedly hypertrophied myocytes, in which the cytoplasm is filled
with numerous, clearly visible vacuoles, the nucleus is hyperchromatic without nucleolus,
and in muscle fibers, the transverse striation is mostly lost. The application of resveratrol
significantly ameliorates the morphological changes caused by hypertension. However,
in the SHR + R group, mild hypertrophy of the myocytes with hypochromatic cytoplasm,
tiny, single, round vacuoles, and large oval nuclei was observed. Additionally, in MHR + R,
resveratrol treatment significantly diminished structural changes in the heart (Figure 5).




Figure 5. Protective effects of resveratrol treatment in the heart tissue of the essential and malig-
nant hypertensive rats, Hematoxylin and Eosin (H&E) method, 200× magnified images. (A) Dif-
fuse vacuolation of the myocytes in the heart tissue of SHR, (B), vacuolar degeneration of the myo-
cytes in the heart tissue of MHR, (C) mild hypertrophy of the myocytes in the heart tissue of SHR 
+ R, and (D) macronodular vacuolation of the myocytes in the heart tissue of MHR + R. 
In edematous myocytes, the cytoplasm is filled with large, clearly visible vacuoles, of 
various shapes, numbers, and arrangements. The nuclei of these cells are large, round, or 
oval and distinctly basophilic. Cardiomyocyte damage score significantly decreased after 
chronic treatment with resveratrol in both treated groups, SHR + R and MHR + R, in com-
parison to their respective controls (p < 0.001). As expected, this parameter was signifi-
cantly better in SHR + R compared to MHR, and its values showed no relevant differences 
in the MHR + R group (Figure 4B). 
Immunohistochemistry of the heart tissue SHR showed that TGF-β was present, with 
a granular appearance, in the cytoplasm. The overexpression of TGF-β was in the myocyte 
of MHR. Treatment with resveratrol induced a total absence of TGF-β, particularly in the 
SHR + R group, and it was partly present in single myocytes of MHR + R (Figure 6). 
Figure 5. Protective effects of resveratrol treatment in the heart tissue of the essential and malignant
hypertensive rats, Hematoxylin and Eosin (H&E) method, 200× magnified images. (A) Diffuse
vacuolation of the myocytes in the heart tissue of SHR, (B), vacuolar degeneration of the myocytes in
the heart tissue of MHR, (C) mild hypertrophy of the myocytes in the heart tissue of SHR + R, and
(D) macronodular vacuolation of the myocytes in the heart tissue of MHR + R.
In edematous myocytes, the cytoplasm is filled with large, clearly visible vacuoles,
of various shapes, numbers, and arrangements. The nuclei of these cells are large, round,
or oval and distinctly basophilic. Cardiomyocyte damage score significantly decreased
after chronic treatment with resveratrol in both treated groups, SHR + R and MHR + R,
in comparison to their respective controls (p < 0.001). As expected, this parameter was
significantly better in SHR + R compared to MHR, and its values showed no relevant
differences in the MHR + R group (Figure 4B).
Immunohistochemistry of the heart tissue SHR showed that TGF-β was present, with
a granular appearance, in the cytoplasm. The overexpression of TGF-β was in the myocyte
of MHR. Treatment with resveratrol induced a total absence of TGF-β, particularly in the
SHR + R group, and it was partly present in single myocytes of MHR + R (Figure 6).
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Figure 6. Resveratrol inhibited inflammation in the heart tissue of the essential and malignant hypertensive rats. The ex-
pression of TGF-β in heart tissue was examined by immunohistochemical staining, magnification 400×. (A) Granular ap-
pearance of TGF-β particular in SHR, (B) intense cytoplasmic staining in heart tissue in MHR, (C) negative immunostain-
ing in the SHR + R group, and (D) significant reduction in TGF-β expression in MHR + R group. 
The protein expression of Bax in heart tissue was in the peripheral parts of the myo-
cytes in the SHR group. In the MHR dark-brown immunoreactive Bax products were seen 
in the cytoplasm of whole cells and the nucleus is difficult to see or not notice. However, 
after resveratrol treatment in the SHR + R group, positive Bax immunoreactivity was im-
munohistochemically demonstrated only of the wall of myocytes, and this expression was 
diffusely distributed in the myocytes of the MHR + R rats (Figure 7). 
Figure 6. Resveratrol inhibited inflammation in the heart tissue of the essential and malignant hypertensive rats. The
expression of TGF-β in heart tissue was examined by immunohistochemical staining, magnification 400×. (A) Granular ap-
pearance of TGF-β particular in SHR, (B) intense cytoplasmic staining in heart tissue in MHR, (C) negative immunostaining
in the SHR + R group, and (D) significant reduction in TGF-β expression in MHR + R group.
The protein expression of Bax in heart tissue was in the peripheral parts of the my-
ocytes in the SHR group. In the MHR dark-brown immunoreactive Bax products were seen
in the cytoplasm of whole cells and the nucleus is difficult to see or not notice. However,
after resveratrol treatment in the SHR + R group, positive Bax immunoreactivity was
immunohistochemically demonstrated only of the wall of myocytes, and this expression
was diffusely distributed in the myocytes of the MHR + R rats (Figure 7).
In the SHR + R group, some myocytes showed positive Bcl-2 immunoreactivity. Slight
positive Bcl-2 immunoreactivity was seen in myocytes of SHR and MHR + R. There were
no findings of positive Bcl-2 immunoreactivities in the myocytes of MHR (Figure 8).




Figure 7. Resveratrol attenuated Bax expression in the heart tissue of the essential and malignant hypertensive rats. The 
expression of Bax in heart tissue was examined by immunohistochemical staining, magnification 400×. (A) The relative 
number of brown stained myocytes in SHR group, (B) expression significantly increased, determined as intensive brown 
cytoplasmic staining widely distributed in heart tissue of the MHR, (C) negative immunostaining in the SHR + R group, 
and (D) myocytes showed rare immuno-positive cells in MHR + R. 
In the SHR + R group, some myocytes showed positive Bcl-2 immunoreactivity. 
Slight positive Bcl-2 immunoreactivity was seen in myocytes of SHR and MHR + R. There 
were no findings of positive Bcl-2 immunoreactivities in the myocytes of MHR (Figure 8). 
Figure 7. Resveratrol attenuated Bax expression in the heart tissue of the essential and malignant
hypertensive rats. The expression of Bax in heart tissue was examined by immunohistochemical
staining, magnification 400×. (A) The relative number of brown stained myocytes in SHR group,
(B) expression significantly increas d, determined as intensive brown cytoplasmic staining widely
distributed in heart tissue of the MHR, (C) negative immunostaining in the SHR + R group, and
(D) myocytes showed rare mmuno-positive cells in MHR + R.




Figure 8. Resveratrol increased Bcl-2 expression in heart tissue of the essential and malignant hypertensive rats. The ex-
pression of Bcl-2 in heart tissue was examined by immunohistochemical staining, magnification 400×, positive reaction—
yellow color. (A) The SHR group showed rare immuno-positive cells, (B) negative immunostaining in the MHR, (C) in-
tense cytoplasmic staining of Bcl-2 in SHR + R group (yellow), and (D) the MHR + R group showed rare immuno-positive 
cells. 
3. Discussion 
Key observations from this study are as follows: (1) MHRs compared to SHRs have 
significant impairments of hemodynamic parameters, oxidative stress, and inflammatory 
status that are accompanied by more intensive histological changes in the heart tissue and 
(2) resveratrol administration on SHRs, as well as MHR animals, elicits cardioprotection, 
and improves hemodynamics and histopathology parameters, which can be attributed to 
antioxidant, anti-inflammatory, and antiapoptotic properties of the resveratrol. 
Our results indicate that, in a genetic model of hypertension, changes in redox and 
inflammatory status compromise cardiovascular function and alter hemodynamic param-
eters in a similar way as shown in the study of Senoner and Dichtl [29]. The L-NAME-
induced malignant hypertension dysregulates production of O2− and, together with the 
interplay between O2− and NO, contributes to an altered cellular redox status and oxida-
tive damage of myocytes in heart tissues. It seems that heart damage is not only related to 
permanently and rapidly increased blood pressure itself (the hemodynamic stress), but 
also to the underlying adverse biochemical alteration (biochemical stress), and, on the 
other hand, to the ability of the heart to withstand with this stress. 
Figure 8. Resveratrol increased Bcl-2 expression in heart tissue of the essential and malignant
hypertensive rats. The expression of Bcl-2 in heart tissue was examined by immunohistochemical
staining, magnification 400×, positive reaction—yellow color. (A) The S R group showed rare
immuno-positive cells, (B) negative immunostaining in the MHR, (C) intense cytoplasmic staining of
Bcl-2 in SHR + R group (yellow), and (D) the MHR + R group showed rare immuno-positive cells.
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3. Discussion
Key observations from this study are as follows: (1) MHRs compared to SHRs have
significant impairments of hemodynamic parameters, oxidative stress, and inflammatory
status that are accompanied by more intensive histological changes in the heart tissue and
(2) resveratrol administration on SHRs, as well as MHR animals, elicits cardioprotection,
and improves hemodynamics and histopathology parameters, which can be attributed to
antioxidant, anti-inflammatory, and antiapoptotic properties of the resveratrol.
Our results indicate that, in a genetic model of hypertension, changes in redox and in-
flammatory status compromise cardiovascular function and alter hemodynamic parameters
in a similar way as shown in the study of Senoner and Dichtl [29]. The L-NAME-induced
malignant hypertension dysregulates production of O2− and, together with the interplay
between O2− and NO, contributes to an altered cellular redox status and oxidative damage
of myocytes in heart tissues. It seems that heart damage is not only related to permanently
and rapidly increased blood pressure itself (the hemodynamic stress), but also to the un-
derlying adverse biochemical alteration (biochemical stress), and, on the other hand, to the
ability of the heart to withstand with this stress.
In the present study, the results indicate that changes in oxidative status in the SHR
are equally important in the development of hemodynamics and pathological alterations,
clearly supporting results from many authors [9,29]. Recent studies have demonstrated
that high blood pressure is a primary and important factor that causes the development of
cardiac hypertrophy [30]. Additionally, some investigations have shown the central role of
ROS in vascular function and inflammation in hypertension [29,31]. Therefore, malignant
hypertension, in our study, was accompanied by a reduction in NO bioavailability, resulting
from reduced NO production and/or increased NO degradation by superoxide anion,
leads to an additional increase in blood pressure and pathological alternation of cardiac
tissue. The investigation of Liu [32] considered NO molecules as a factor that mediates
the vasodilator activity of resveratrol. Similar results were observed in different animal
models of hypertension [3]. Previously, we have shown resveratrol to decrease the high
blood pressure and to prevent remodeling of the aorta walls of SHRs and MHRs [5]. In this
study, resveratrol in both models of hypertension reduced O2− and increased the level of
the vasodilator NO, which protects against high blood pressure and subsequent cardiac
hypertrophy. We have shown that elevated blood pressure declined by 18.2% in SHRs and
16.7% in MHRs after chronic resveratrol treatment. Generally, chronic pressure overload
is characterized by an increase in total vascular resistance, which was confirmed in both
our hypertensive groups. This value was significantly reduced in both resveratrol treated
groups, which could indicate that this polyphenol is a potential enhancer of vascular
function. These results give hope that resveratrol could be a great ally in all degrees
of hypertension, especially in association with the standard FDA recommended drugs.
Actually, pharmacological intervention studies have shown that the reduction of just
10% of the values of the blood pressure resulted in a 40% reduction in mortality from
cardiovascular accidents and 16%–20% from coronary accidents.
Although, it is well-known that lipide peroxidation has been increased in hyperten-
sive rats [28]. The attenuation of antioxidant activity, as well as accumulation of protein
oxidation and lipid peroxidation products in hypertensive models, indicate that there is
an excessive amount of reactive oxygen species and a reduction in antioxidant activity,
which is consistent with the results of other authors [33]. Several studies have shown
that oxidative stress plays a pivotal role in mediating the production and secretion of
cytokines [11,34], thus linking ROS with inflammation, endothelial activation, and dys-
function. The mechanisms by which oxidative stress elicits endothelial cell injury during
hypertension are likely to include induction of inflammatory processes and activation of
cellular apoptotic pathways [29]. In the present study, MHRs had both exacerbated levels
of lipids and protein oxidative products, as well as significantly reduced antioxidative
potential concerning the SHR. Resveratrol is known to promote antioxidant defenses by
regulating a host of antioxidant enzyme [35,36]. Additionally, resveratrol improved ox-
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idative damage in vasculature, heart, skeletal muscle, kidney, and brain tissues caused by
high blood pressure [23,36–39].
In our study resveratrol activates the antioxidant system, including superoxide dismu-
tase, glutathione peroxidase and catalase, leading to a decrease in the prooxidative balans.
We have found that the activity of the antioxidant enzymes was markedly increased after
treatment with resveratrol in both SHRs and MHRs. An increase in antioxidative enzyme
production caused by resveratrol was involved to some degree in the mechanism by which
resveratrol positively modulates blood pressure. Consequently, in this study, resveratrol
could exert a positive effect on heart tissue via a direct modification of antioxidant defense
or by decreasing blood pressure in both SHRs and MHRs.
Eiserich et al. [40] have shown that MPO diminishes the bioavailability of NO and
impairs NO-dependent vessel relaxation, which is confirmed in our results for both SHR
and MHR models. As described previously, NO has an important role in vascular tone [41].
In healthy subjects, NO causes vasodilation of the blood vessels. In contrast, hypertension
decreases bioavailability of NO, attenuating vasodilatation of peripheral blood vessels and
remarkably elevating vasoconstriction of conduit arteries [1]. In this study, we assume
that resveratrol treatment in both SHRs and MHRs improved NO bioavailability, at least
in part, through MPO inhibition. Therefore, our study, for the first time, shows effects
of resveratrol on the MPO activity in heart tissue, particularly in the model of malignant
hypertension, as well as the beneficial effects of resveratrol treatment in this model.
Elevated blood pressure induces structural changes in the vasculature, including
hypertrophy and overproduction of TGF-β. In different models of the arterial hypertension
in aorta tissue, an increased expression of TGF-β has been reported [5,42]. The previously
published papers have shown that TGF-β and bone morphogenetic protein pathways
may regulate the change in expression of ~19% of hypertension-responsive genes [43].
Otherwise, uncontrolled ROS production leads to increased expression and secretion of
TGF-β [44]. In the presented study, myocytes of MHRs showed TGF-β overexpression,
compared with the degree of expression in myocytes of control hearts. Overexpression
of TGF-β in the heart tissue of the MHRs promotes hypertrophy of the myocytes and an
increase in the number of microvessels. These processes result in rupture and degrada-
tion of myofilaments accompanied with cardiac apoptosis. Resveratrol had a maximal
effect in reversing them in SHRs. Additionally, in malignant hypertensive animals, treat-
ment with resveratrol led to a tissue structure that was almost identical to that of the
untreated controls. The overexpression of TGF-β was rare in salvaged myocytes of the
SHRs, but it was moderately frequent in heart tissue of malignant hypertensive rats after
resveratrol treatment.
Hockenbery et al. [16] found that Bcl-2 protein is not expressed in normal cardiac tis-
sues. Some research conformed Bcl-2 as a prototype for an antideath or survival factor [17].
In this study, there was no evidence of positive immunoreactivity in the hearts of MHRs,
as described previously [45]. Positive Bcl-2 immunostaining in myocytes after resveratrol
treatment promotes this polyphenol as an antiapoptic factor.
The Bax protein is found in various tissues [46]. Additionally, it is a member of
the Bcl-2 family and, when overexpressed, accelerates the apoptotic death induced by
cytokines [17]. This study showed Bax overexpression in the myocytes of MHRs, while it
was rarely present in the SHRs. After resveratrol treatment, there is no Bax expression in
the myocytes of SHRs, but it is expressed only in the bordering regions of myocytes of the
MHRs. Our study revealed that in the salvaged myocytes after resveratrol treatment, Bcl-2
protein is expressed, and overexpression of Bax is rare. These data suggest that Bcl-2 activa-
tion could impede Bax, thus reducing cell apoptosis. Therefore, it is reasonable to speculate
that resveratrol might be a potential therapeutic target to reverse vascular remodeling and
retard the progression of hypertrophy changes in heart tissue of hypertensive animals.
Our results show that resveratrol possesses anti-inflammatory and antiapoptotic
properties in both models of hypertension, with more pronounced effects in malignant
hypertensive rats. Actually, resveratrol treatment normalized the myocardial ultrastructure,
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as evidenced by intact myofibrils and a reduction in number of vesicula in myocytes. This
effect of resveratrol on cell survival may be attributed to multiple mechanisms, including
prevention of cardiomyocyte apoptosis, regulation of inflammation, and reduction in
oxidative stress.
4. Materials and Methods
4.1. Materials
All the environmental conditions, as well as procedures adopted for housing and
handling of experimental animals, were in strict compliance with Guidelines for Laboratory
Animal Welfare, Ethics Committee for Experiments on Animals of the Institute for Medical
Research (IMR), University of Belgrade, Serbia, which was adopted by the current National
Law on Animal Welfare (Serbian Gazzette, No. 41/2009). The study protocol was approved
by the Ethics Committee for Experiments on Animals issued by IMR (No. 0316-1/11).
The experiments were performed on 6-month-old female SHRs (200 to 250 g) bred at
the IMR. They were descendants of breeders originally obtained through Taconic Farms,
Germantown, NY, USA. The experimental animals were housed in groups of four in
plastic cages (Macrolon® cage type 4, Bioscape, Castrop-Rauxel, Germany) with sawdust
bedding (Versele-Laga, Deinye, Belgium) certificated as having contaminant levels below
toxic concentrations. The environmental conditions were controlled and monitored by a
central computer-assisted system with a temperature of 22 ± 2 ◦C, a relative humidity
of 55% ± 15%, 15–20 air changes/h, and artificial lighting of approximately 220 V (12 h
light/dark cycle). The experimental animals had free access to food, commercial pellets
for rats (Veterinarski Zavod Subotica, Victoria group, Subotica, Serbia) and tap water from
municipal mains, filtered through a 1.0 µm filter (Skala Green, Subotica, Serbia).
All animals were examined for control values of systolic blood pressure by an indirect
method using a tail-cuff, pneumatic pulse detector and direct recorder (Physiograph
Four, Narco Bio-System, Houston, TX, USA). After ensuring that all animals had been
hypertensive, they were divided into four groups according to the 4-week drug treatment.
The first group was SHR (n = 12), who received tap water 0.5 mL by gavage. The second
group was SHR + R group (n = 12), who were treated with resveratrol (Sigma-Aldrich,
St. Louis, MO, USA) with a dose of 10 mg/kg/day by gavage. The malignant hypertensive
group (MHR) represents the SHRs that were treated with L-NAME (Sigma-Aldrich, St.
Louis, MO, USA), a nonselective inhibitor of NO synthase enzyme dissolved in tap water
in a dose of 10 mg/kg/day (n = 12). The fourth group was MHR + R, SHRs (n = 12) treated
with the combination of L-NAME and resveratrol in the same dosages (Figure 1A).
4.2. Hemodynamic Measurements
At the end of treatment, all animals were anesthetized (35 mg/kg ip sodium pento-
barbital) and then hemodynamic and biochemical studies were performed. SAP and HR
were measured directly through a femoral artery catheter (PE–50, Clay-Adams Parsippany,
NJ, USA) using a low volume displacement transducer P23 Db (Statham, Oxnard, CA,
USA), and recorded on a direct writing recorder. Additionally, their left carotid arteries and
right jugular veins were prepared for CO measurement using a previously described [47]
modification of Coleman’s application of the dye dilution technique. Indocyanine green
was used as the indicator, and a recording densitometer (Beckman Instruments, Columbia,
MD, USA) was utilized for the determination of dye in the blood and registration of the
dilution curve. TVR was calculated by dividing the mean arterial pressure by CO and
expressed as mmHg ×min × kg/mL.
4.3. Redox State of Heart
Hearts were harvested, weighed, and stored at −70 ◦C for later analysis. TBARSs, as a
marker of lipid peroxidation, were measured by using 4,6-dihydroxy-2-mercaptopyrimidine
according to the method of Ohkawa et al. [48]. AOPP were measured in an acidic condition
in the presence of potassium iodide [49]. The concentration of NO2− was measured in heart
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tissue by the Griess reagent method, as previously described [5]. Quantification of free
protein thiol groups was determined by derivatization with 5,5′-dithiobis(2-nitrobenzoic
acid) (DTNB) by the Ellman method [50]. The concentration of O2− in heart tissue was
measured at 530 nm after the reaction of nitro blue tetrazolium in TRIS buffer [51]. Deter-
mination of PAB in heart tissue was performed using 3,3′, 5,5′-tetramethylbenzidine as a
chromogen [52]. Myeloperoxidase enzyme activity heart samples were determined by the
o-dianisidine-H2O2 method, as described by Kothari et al. [13].
The activities of antioxidant enzymes, SOD, CAT, GR and GPx, were measured in
heart homogenates by the spectrophotometric method, as previously described [53–56].
All spectrophotometric analyses of the heart redox state and antioxidant enzyme
activities were performed with an Ultrospec 3300 pro UV/Visible spectrophotometer
(Amersham Biosciences Corp., Piscataway, NJ, USA).
4.4. Histopathological Examination
The heart was removed, and tissue slices were fixed in 10% neutral-buffered formalde-
hyde, embedded in paraffin and sectioned. The sections, 2 µm thick, were stained by the
hematoxylin and eosin (H&E) method. From each specimen, the visual fields, magnified by
20× and 40× were analyzed by using a light microscope (Olympus-2, Tokyo, Japan). Semi-
quantitative analysis, as we previously described using the modified Billingham scale [57],
assessed the degree of the tissue’s damage according to a five-point semiquantitative scale
(Table 2). Eight tissue samples from each group were available, and five sections from each
tissue samples were analyzed. All pathohistological examinations were performed by two
independent observers as a blind study with no prior knowledge of the treatment given
to the animals. The sum of these changes represented the Cardiomyocyte Damage Score
(CDS) [57].
Table 2. Tissue damage score for the heart alterations (CDS—Cardiomyocyte Damage Score).
Degree Description
0 Normal histological structure of the heart.
1 A slight loss of transverse striation was observed in individual cells.
2 Smaller groups of cells with a pronounced loss of transverse striation and theappearance of small vacuoles in the sarcoplasm.
3 A larger number of cells with a pronounced loss of transverse striation and theappearance of large vacuoles in the sarcoplasm.
4 Diffuse vacuolar degeneration of cardiomyocyte cytoplasm followed byvacuolar degeneration.
4.5. Immunohistochemistry Examination
Immunostaining was applied on 5 µm thick paraffin sections. After deparaffinization
and rehydration, the sections were treated by microwave for 20 min at 400 Win citrate
buffer (pH 6.0). After antigen retrieval, samples were incubated overnight with primary
antibody for TGF-β (Millipore, MAB1032, TB21; dilution 1:1000), Bax (Millipore, Billerica,
MA, USA, dilution 1:250) and Bcl-2 (Millipore, Billerica, MA, USA, dilution 1:200). Sections
were then treated with EnVisionTMDetection System (DAKO, GmbH, Jena, Germany)
using a biotinylated secondary antibody. Sections from the testicle, serving as a positive
control, were processed at the same time, and handled in the same way. Negative controls
were performed by omitting the first antibody. The slides were evaluated using a light
microscope (Olympus-2, Tokyo, Japan). Slides were evaluated by two of the authors,
unaware of immunohistochemical or clinical data using ImageJ, a public domain, Java-
based image processing program developed at the National Institute of Health, Bethesda,
Maryland, USA.
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4.6. Statistical Analysis
The data were analyzed by the statistical software package STATISTICA 12, StatSoft
Inc, (Tulsa, OK, USA). Results are expressed as mean ± S.D. One way analysis of variance
(ANOVA) was applied as appropriate. The differences between examined groups were
considered significant if p < 0.05.
5. Conclusions
In conclusion, resveratrol, apart from its well-characterized activities as an antioxidant,
significantly induced reduction in blood pressure through the direct and enzyme-linked
ROS neutralization. It also protects heart tissue of hypertensive rats by blunting myeloper-
oxidase and TGF-beta activity and suppressing the apoptotic process. While conventional
therapies targeting control blood pressure are undoubtedly useful, newer approaches,
including natural products such as resveratrol, may provide additional benefits against
general and malignant hypertension. Resveratrol has successfully been shown to impart
protective effects through various mechanisms, thereby making its a potential therapeutic
agent for managing severe forms of hypertension.
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